Ray has nearly 20 years’ experience in health economics and outcomes research (HEOR), and leads projects principally focused on developing decision-analytic models for use during pricing and reimbursement negotiations. These models range from complex HTA models suitable for NICE, CADTH, and PBAC to simple budget impact models for use during formulary discussions. Ray also develops early-stage models for strategic planning and gap analysis, conducts burden of illness studies for HTA assessments, and supports RCT and observational study design so appropriate data is collected for economic analyses. His experience covers Europe, North America, Australia, and Asia, and several therapy areas including oncology, multiple sclerosis, respiratory disease, infectious disease, CVD, diabetes, and rare/orphan disease.
Ray was previously an Associate Principal at IQVIA Global Consulting, specializing in health economics. He has also held roles as European HEOR director at Astellas, UK and Ireland HEOR team leader at Boehringer Ingelheim, Technical Lead for Economic Evaluation at Heron Evidence Development (now Parexel), and Head of Quantitative Risk Assessment at the Health Protection Agency (now Public Health England).
Ray has presented studies at international conferences and authored publications for Nature, Emerging Infectious Diseases, Journal of Economics, PharmacoEconomics, Heart, and Value in Health. He has a PhD in economic modelling from the University of Strathclyde, an MSc in mathematical modelling from the University College London, and a BSc (Hons) in mathematics from the University of Leicester.